Skip to main content

Table 1 Pathological and clinical characteristics of HER2-positive patients at baseline

From: Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

Characteristics

Total

No. patients (%)

P

No. patients (%)

P

CTC Count at baseline

CTC Count at baseline

≥1

<1

≥5

<5

Overall

60

27 (45.0)

33 (55.0)

 

12 (20.0)

48 (80.0)

 

Age (years)

       

  Mean

48.8

46.6

50.6

0.155

46.6

49.4

0.420

  Range

25-75

25-68

33-75

25-58

32-75

Histology

       

  Ductal

49

24 (49.0)

25 (51.0)

0.130

10 (20.4)

39 (79.6)

0.481

  Lobular

3

0 (0.0)

3 (100.0)

0 (0.0)

3 (100.0)

  Others

8

3 (37.5)

5 (62.5)

2 (25.0)

6 (75.0)

ER

       

  Positive

24

9 (37.5)

15 (62.5)

0.430

4 (16.7)

20 (83.3)

0.746

  Negative

36

18 (50.0)

18 (50.0)

8 (22.2)

28 (77.8)

PR

       

  Positive

22

9 (40.9)

13 (59.1)

0.789

4 (18.2)

18 (81.8)

1.000

  Negative

38

18 (47.4)

20 (52.6)

8 (21.1)

30 (78.9)

No. of Metastasis

       

  1

19

5 (26.3)

14 (73.7)

0.057

1 (5.3)

18 (94.7)

0.082

  ≥2

41

22 (53.7)

19 (46.3)

11 (26.8)

30 (73.2)

Metastatic sites

       

  Bone only

4

2 (50.0)

2 (50.0)

0.314

0 (0.0)

4 (100.0)

0.270

  Visceral only

7

2 (28.6)

5 (71.4)

1 (14.3)

6 (85.7)

  Bone and visceral

30

18 (60.0)

12 (40.0)

8 (26.7)

22 (73.3)

DFS

       

  ≤12 months

11

3 (27.3)

8 (72.7)

0.306

3 (27.3)

8 (72.7)

0.671

  >12 months

39

19 (48.7)

20 (51.3)

7 (17.9)

32 (82.1)

Therapy line

       

  1

15

7 (46.7)

8 (53.3)

0.470

3 (20.0)

12 (80.0)

0.329

  2

9

2 (22.2)

7 (77.8)

1 (11.1)

8 (88.9)

  3

13

7 (53.8)

6 (46.2)

1 (7.7)

12 (92.3)

  ≥ 4

23

11 (47.8)

12 (52.2)

7 (30.4)

16 (69.6)